

The Carotid Artery Atherosclerosis Burden and Its Relation to Cardiovascular Risk Factors in Black and White Africans with Established Rheumatoid Arthritis: A Cross-sectional Study

AHMED SOLOMON, ANGELA J. WOODIWISS, ABU T. ABDOOL-CARRIM, BELINDA A. STEVENS, GAVIN R. NORTON, and PATRICK H. DESSEIN

ABSTRACT. *Objective.* Black Africans currently experience a distinctly low frequency of atherosclerotic cardiovascular disease. Whether this protection persists in those with rheumatoid arthritis (RA) is unknown. We compared the carotid atherosclerosis burden and its relationships with cardiovascular (CV) risk factors between Africans with RA from a developing black and developed CV population.

Methods. We performed high resolution B-mode ultrasonography and assessed CV risk factors in 243 patients with established RA, of whom 121 were black and 122 white. Data were analyzed in age, sex, and healthcare center-adjusted regression models.

Results. The mean \pm SD common carotid intima-media thickness (cIMT) was 0.694 ± 0.097 mm in black and 0.712 ± 0.136 mm in white patients (adjusted $p = 0.8$). Plaque prevalence was also similar in black compared to white cases (35.5% and 44.3%, respectively; adjusted OR 0.83, 95% CI 0.32–2.20, $p = 0.7$). Interactions between population grouping and several CV risk factors were independently associated with cIMT and plaque. In stratified analysis, that is, in each population group separately, risk factors associated with cIMT or/and plaque comprised the systolic blood pressure ($p = 0.02$), serum cholesterol/high-density lipoprotein cholesterol ratio ($p = 0.004$), C-reactive protein concentrations ($p = 0.01$), and the presence of extraarticular manifestations ($p = 0.01$) in whites but, contrastingly, the Arthritis Impact Measurement Scales tension score ($p = 0.04$) and use of nonsteroidal antiinflammatory agent ($p = 0.03$) in black patients. The Framingham score was significantly associated with atherosclerosis only in whites ($p < 0.0001$).

Conclusion. The carotid atherosclerosis burden is similar in black compared to white Africans with RA, but relationships between modifiable CV risk factors and atherosclerosis vary substantially among Africans with RA. (J Rheumatol First Release July 1 2012; doi:10.3899/jrheum.120073)

Key Indexing Terms:

ATHEROSCLEROSIS
CARDIOVASCULAR

RHEUMATOID ARTHRITIS
RISK FACTORS

DEVELOPING POPULATION
AFRICANS

From the Department of Rheumatology, Charlotte Maxeke Johannesburg Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand; and Department of Vascular Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Supported by a Medical Research Council Grant.

A. Solomon, MBBCh, Department of Rheumatology, Charlotte Maxeke Johannesburg Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand; A.J. Woodiwiss, PhD; G.R. Norton, MBBCh, PhD; P.H. Dessein, MD, FCP(SA), FRCP(UK), PhD, Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand; A.T. Abdool-Carrim, MBBCh, FRCS(Edin), Department of Vascular Surgery, Faculty of Health Sciences, University of the Witwatersrand; B.A. Stevens, B Tech, Vascular Laboratory, Milpark Hospital, Johannesburg.

Address correspondence to Dr. P.H. Dessein, PO Box 1012, Melville 2109, Johannesburg, South Africa. E-mail: Dessein@telkomsa.net

Accepted for publication May 18, 2012.

Rheumatoid arthritis (RA) is a chronic inflammatory and destructive joint disease that is recognized to enhance the risk for atherosclerotic cardiovascular disease (CVD) events about 2-fold¹. The standardized CV mortality ratio is increased by 50% in RA and thereby accounts for most of the excess overall mortality caused by this disease².

CVD in RA is brought about by traditional and nontraditional CV risk factors or disease characteristics, particularly inflammation^{3,4,5,6,7,8,9,10}. Importantly also in this context, whereas genetic factors contribute substantially to CVD in the population at large¹¹, the same likely applies in RA. Indeed, genetic polymorphisms that are implicated in inflammatory pathways such as the TNFA-308 (rs1800629)¹² and the CCR5Δ32 variant¹³ and metabolic pathways including the acid phosphatase locus 1*C allele¹⁴ were recently shown to be associated with CVD in patients with RA. Further, genes that

influence RA susceptibility can influence CVD¹⁵ and its conventional risk factors in RA¹⁶. These findings may enable elucidation of the molecular mechanisms involved, discovery of new therapeutic targets, and optimization of risk assessment in RA-related CVD.

Our knowledge of CVD in the general population and even more in persons with chronic inflammatory diseases such as RA largely derives from studies that were performed in developed populations^{17,18}. However, ~80% of CVD now arises in middle and low-income groups or in developing countries¹⁷. Further, the effect of individual CV risk factors on CV events may differ in the developing compared to the developed nations^{18,19,20}.

South Africa, a sub-Saharan country with 50 million inhabitants, has become the most unequal society in the world²¹. A minority of South Africans follow a westernized lifestyle, live in modern cities, and represent a developed and mostly white population, whereas the majority still follow a more traditional lifestyle, live outside these cities, and typify a developing and predominantly black population^{20,22,23}. Accordingly, these populations are at different stages of the epidemiological health transition, and the incidence of CVD is still distinctly uncommon in black compared to white sub-Saharan Africans^{18,20,22}. However, whether this protection is present in black Africans in the face of established RA is unknown. The South African Heart Association recommends the European Society of Cardiology and European Atherosclerosis Society guidelines on CV risk assessment and management irrespective of population grouping or socioeconomic factors²⁴. In keeping with an earlier epidemiological transition stage, we recently identified several disparities in individual CVD risk factor profiles between blacks and other Africans with RA (whites, Asians, and people of mixed ancestry) but the overall traditional and nontraditional CVD risk burden was similar in both populations¹⁸. In our present study, we compared the ultrasonographically determined carotid atherosclerosis burden, a predictor of CVD events in the general population and in patients with RA^{24,25,26}, in black and white Africans with RA. Additionally, we investigated whether disparities exist in the relationships of modifiable CVD risk factors with carotid atherosclerosis between the 2 populations.

MATERIALS AND METHODS

Study populations. We enrolled patients during the period March 23 to November 25, 2009, who met the American College of Rheumatology criteria for RA²⁷, at the Charlotte Maxeke Johannesburg Academic Hospital (public healthcare) and Milpark Hospital (private healthcare) in Johannesburg (Table 1). None of the recorded data have been reported previously. Only patients that had used disease-modifying agents were included; 4 invited patients refused to participate and those known to be infected with the human immunodeficiency virus (HIV) were excluded. Considering the aims of the investigation, we also excluded patients of mixed ancestry and Asians with RA because they are not consistently at the same epidemiological transition stage as either black or white Africans²⁰. The HIV prevalence in South Africans aged 50 years and older is currently 5.7%²⁸; and Asians and people of mixed ancestry comprise 11% and 8%, and 8% and 5% of patients with RA in our public and private healthcare centers, respectively¹⁸.

Table 1. African patients (n = 243) with RA by sex and healthcare center.

	Black, n (%)	White, n (%)	p
All participants	121 (49.8)	122 (50.2)	—
Sex			
Women	108 (89.3)	95 (77.9)	
Men	13 (10.7)	27 (22.1)	0.02
Healthcare center			
Public	117 (96.7)	22 (18.0)	
Private	4 (3.3)	100 (82.0)	< 0.0001

RA: rheumatoid arthritis.

Whereas patients attending South African public healthcare centers currently have no access to use of biological agents for RA, this intervention was employed in 10 private-care patients (tumor necrosis factor- α blockade in 9 and rituximab in 1), all whites. Biological and nonbiological disease-modifying antirheumatic drugs (DMARD) were grouped into the same single variable for the purpose of our data analysis. Nonsteroidal antiinflammatory drugs (NSAID) used in black and white patients comprised nonselective cyclooxygenase (COX) inhibitors (indomethacin and ibuprofen) in the former and both traditional NSAID (ibuprofen, diclofenac, and meloxicam) and selective COX-2 inhibitors (celecoxib and etoricoxib) in the latter.

The study was approved by the Ethics Committee for Research on Human Subjects (Medical) of the University of the Witwatersrand. Written informed consent was obtained from each patient.

Assessments. CV risk factors that were assessed are presented in Table 2. Data were missing in < 5% for any of the recorded characteristics. All patients fasted for at least 8 h prior to blood sampling. Hypertension was defined as average systolic blood pressure \geq 140 mm Hg or/and diastolic blood pressure \geq 90 mm Hg or/and current use of antihypertensive medications. Serum total cholesterol and low and high-density lipoprotein (LDL, HDL) concentrations were determined by enzymatic assays, serum triglyceride concentrations by the glycerol phosphate oxidase method, and C-reactive protein (CRP) concentrations by nephelometry. Dyslipidemia was diagnosed when the atherogenic index, i.e., cholesterol/HDL cholesterol ratio, was $>$ 4, and the proatherogenic non-HDL concentrations were calculated by subtracting HDL cholesterol from total cholesterol concentrations^{18,29,30}. Current smoking status was assessed. Diabetes was defined as plasma glucose concentration \geq 7 mmol/l or/and use of glucose-lowering agents. We recorded alcohol use (at least 1 unit per month), exercise (at least once per month and including time spent in walking, that is, to reach public transport), marital status, education level (years of education), body mass index (BMI), waist circumference, and the waist-hip ratio. Symptoms of tension and depression were estimated by the Arthritis Impact Measurement Scales (AIMS)³¹.

RA characteristics evaluated as potential CV risk factors comprised the rheumatoid factor status, extraarticular manifestations (see below), use of antirheumatic agents including NSAID, prednisone, and number of prescribed DMARD, RA duration, the Disease Activity Score in 28 joints (DAS28), serum CRP concentrations, the Stanford Health Assessment Questionnaire Disability Index, and the number of deformed joints^{18,32}. Extraarticular manifestations included current or previously recorded (hospital record review) presence of pericarditis, pleuritis, Felty's syndrome, cutaneous vasculitis, neuropathy, scleritis or episcleritis, retinal vasculitis, glomerulonephritis, vasculitis affecting other organs, amyloidosis, keratoconjunctivitis sicca, xerostomia, Sjögren's syndrome, pulmonary fibrosis, bronchiolitis obliterans organizing pneumonia, cervical myelopathy, and subcutaneous nodules and rheumatoid nodules in other locations^{32,33}.

Two authors (BAS, AS) performed the carotid artery ultrasound measurements in private and public healthcare patients, respectively. Both operators obtained images of at least 1-cm length of the distal common carotid arteries for measurement of the intima-media thickness of the far wall from an optimal angle of incidence, defined as the longitudinal angle of approach where

Table 2. Cardiovascular risk factor profiles in black compared to white patients with RA. Dichotomous variables are expressed as proportions or percentages and continuous characteristics as mean ± SD. Significant associations are shown in bold type.

Characteristics	Black, n = 121	White, n = 122	OR* (95% CI)
Female sex	89.3	77.9	—
Major conventional CV risk factors			
Hypertension	71.9	45.9	2.43 (1.00–5.94)
T chol/HDL chol > 4	22.2	15.8	1.78 (0.56–5.64)
Smoking	3.3	9.9	0.22 (0.05–1.05)
Diabetes	16.5	7.4	1.78 (0.47–6.65)
Other conventional CV/predisposing risk factors			
Alcohol use	2.5	38.0	0.05 (0.01–0.15)
Exercise	39.7	33.3	0.93 (0.39–2.18)
Marital status			
Unmarried	38.0	7.4	2.88 (0.92–9.05)
Married	37.2	75.4	0.52 (0.22–1.26)
Divorced	8.3	9.0	0.82 (0.19–3.42)
Widowed	16.5	8.2	1.56 (0.38–6.39)
Nonconventional CV risk factors			
Rheumatoid factor-positive	50.5	48.3	1.02 (0.38–2.75)
Extraarticular manifestations	2.5	12.3	0.19 (0.05–0.67)
Antirheumatic agent used			
NSAID	7.4	27.0	3.18 (0.56–18.16)
Prednisone	1.7	3.3	0.50 (0.09–2.78)
Continuous variables, mean ± SD			p*
Age, yrs	55.8 ± 10.1	58.2 ± 11.4	—
Major conventional CV risk factors			
Systolic blood pressure	140 ± 24	128 ± 17	0.5
Diastolic blood pressure	86 ± 15	79 ± 9	0.02
T chol, mmol/l	4.7 ± 0.9	5.0 ± 1.1	0.03
HDL chol [†] , mmol/l	1.48 ± 1.34	1.61 ± 1.03	0.05
T chol/HDL chol	3.2 ± 1.1	3.2 ± 1.0	0.6
LDL chol, mmol/l	2.6 ± 0.8	2.8 ± 0.9	0.2
Non-HDL chol, mol/l	3.1 ± 0.9	3.3 ± 1.0	0.2
Pack-year history of smoking [†] , yrs	0.1 ± 1.7	2.8 ± 5.2	0.008
Major risk factors, n	1.2 ± 0.8	0.8 ± 0.7	0.1
Framingham score [†]	2.6 ± 3.0	2.9 ± 3.0	0.5
Other conventional CV/predisposing risk factors			
Exercise [†] , hours per wk	0.6 ± 2.0	0.6 ± 2.1	0.2
Education, yrs	7.4 ± 4.1	13.0 ± 2.7	0.0002
BMI, kg/m ²	29.4 ± 6.6	25.6 ± 4.7	0.003
Waist circumference, cm	93.4 ± 13.4	88.8 ± 13.0	0.08
Waist/hip [†]	0.85 ± 3.65	0.86 ± 1.11	0.6
Triglycerides [†] , mmol/l	1.08 ± 1.71	1.08 ± 1.51	0.6
AIMS tension [†]	3.8 ± 1.5	2.8 ± 1.7	0.1
AIMS depression [†]	3.2 ± 1.5	1.8 ± 1.7	0.1
Nonconventional CV risk factors			
Disease duration, yrs	12.8 ± 9.2	14.3 ± 9.3	0.5
DAS28	4.1 ± 1.3	3.6 ± 1.6	0.3
CRP [†] , mg/l	7.0 ± 3.1	4.3 ± 3.7	0.9
HAQ score [†]	0.54 ± 0.41	0.37 ± 0.43	0.5
Deformed joints [†]	6 ± 2	4 ± 4	0.08
No. DMARD	2.5 ± 1.0	2.2 ± 0.9	0.4

CV: cardiovascular; T: total; chol: cholesterol; BMI: body mass index; AIMS: Arthritis Impact Measurement Scales; DAS28: Disease Activity Score in 28 joints; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; DMARD: disease-modifying antirheumatic drugs; RA: rheumatoid arthritis; HDL: high-density lipoprotein; NSAID: nonsteroidal antiinflammatory drug; LDL: low-density lipoprotein. * OR and p value for comparisons between black and white Africans after adjustment for age, sex, and healthcare center as well as lipid-lowering and antihypertensive agents in models that include lipid and systolic and diastolic blood pressure variables, respectively. † Logarithmically transformed variables for which geometric means (SD) are given.

both branches of the internal and external carotid artery are visualized simultaneously³⁴. They used high-resolution B-mode ultrasound (Image Point, Hewlett Packard, Andover, MA, USA, and SonoCalc IMT, Sonosite Inc., Bothell, WA, USA; used by BAS and AS, respectively) with linear array 7.5-MHz probes. Details of the methodology used by BAS were as reported³. The equipment used by AS involved application of a unique semiautomated border detection program that was found to provide highly reproducible results³⁴. The intima-media thicknesses in the left and right common carotid artery were measured; carotid intima-media thickness (cIMT) was defined as the mean of these. Carotid artery plaque was defined as a focal structure that encroaches into the arterial lumen by at least 0.5 mm or 50% of the surrounding intima-media thickness value, or demonstrates a thickness of > 1.5 mm as measured from the media-adventitia interface to the intima-lumen interface³⁵. Both operators were blinded to the CV risk profiles of the patients. Repeat ultrasound examinations by both operators on 23 patients revealed Spearman correlations between repeat cIMT measurements of 0.983 for BAS and 0.956 for AS, and the correlation between measurements made by BAS and AS was 0.926. Both operators identified carotid artery bulb or/and internal carotid artery plaque in 11 of these 23 patients with full agreement.

Statistical methods. We grouped the CV risk factors into 3 categories¹⁸ (Table 2): (1) the major modifiable conventional risk factors of hypertension, dyslipidemia, smoking, and diabetes that feature in the Framingham score; (2) other CV conventional risk or predisposing factors including alcohol use, exercise, marital status, education level, BMI, waist circumference, waist-hip ratio, serum triglyceride concentrations, and the AIMS tension and depression scores; and (3) nonconventional risk factors consisting of RA characteristics.

Dichotomous variables are expressed as proportions or percentages and continuous variables as mean \pm SD. Non-normally distributed characteristics were logarithmically transformed prior to statistical analysis and for these variables geometric means \pm SD are given. The selection of potential confounders in multivariate regression models was based on biological plausibility.

Relationships between population grouping, or in the present context, also ethnic grouping (EG) and CV risk factors were investigated in multivariable logistic and linear regression models as appropriate and with consistent adjustment for age, sex, and healthcare center attendance. Prescribed antihypertensive therapy and statin use were further adjusted for when assessing associations with blood pressure and lipid variables, respectively.

The mean \pm SD cIMT was compared between black and white patients by the Student t test and in age, sex, and healthcare center-adjusted linear multivariate logistic regression analysis; plaque prevalence was compared in univariate and age, sex, and healthcare center-adjusted multivariate logistic regression models.

To determine whether there were disparities in the relationships of modifiable CV risk factors with atherosclerosis in black compared to white patients, we assessed the associations of interactions between EG and the recorded risk factors with cIMT and plaque in multivariable regression models in which age, sex, and healthcare center and the individual terms were adjusted for, and subsequently performed stratified analysis.

The study was 95% powered to detect a significant ($p < 0.01$) difference in mean cIMT of 0.100 mm (the expected increase per 10-year age increment³⁶) in multiple regression analysis with inclusion of 3 covariates between black and white Africans with RA. Statistical computations were made using the GB Stat™ program (Dynamic Microsystems, Silver Spring, MD, USA).

RESULTS

Patient characteristics. Patient characteristics are shown in Tables 1 and 2. A total of 243 patients comprising 121 blacks and 122 whites were investigated. Black patients were more often women ($p = 0.02$) and were on average 2.4 years younger ($p = 0.08$) than their white counterparts. About 97% of black patients and 82% of whites were seen in public and private care, respectively.

Antihypertensives were used more frequently in black patients (54.6% vs 41.8%; OR 1.67, 95% CI 1.00–2.78) and statins more often in whites (36.1% vs 19.0%; OR 2.40, 95% CI 1.33–4.33). In confounder-adjusted analysis (Table 2), compared to whites, black patients experienced a higher prevalence of hypertension and had a higher diastolic blood pressure, but smoked less; their mean serum total cholesterol concentration was lower, but with concurrent numerically lower HDL cholesterol concentrations the total cholesterol/HDL cholesterol ratio was similar. These results translated into an overall major conventional CV risk burden, as estimated by the number of major risk factors and the Framingham score, that was similar in black and white patients. Disparities in other conventional CV/predisposing risk factors (Table 2) included a higher BMI, less frequent alcohol use, and a lower education level in black compared to white patients.

Among the nonconventional or predisposing CV risk factors shown in Table 2, black patients experienced extraarticular manifestations less often than their white counterparts. Although the geometric mean CRP concentrations were substantially higher (2.7 mg/l) in black compared to white patients ($p = 0.002$ in univariate analysis), this difference was not significant ($p = 0.9$) in age, sex, and healthcare center-adjusted analysis.

Carotid atherosclerosis in black and white Africans with RA. The mean cIMT was 0.694 ± 0.097 mm in black and 0.712 ± 0.136 mm in white patients with RA ($p = 0.3$). Forty-three of the black (35.5%) and 54 white patients (44.3%) had plaque ($p = 0.3$). As illustrated in Figure 1, these results were unaltered after adjustment for age, sex, and healthcare center and after further adjustment for disease duration and prednisone use as well as CV risk factors that differed between black and white patients (Table 2) and included hypertension, total and HDL cholesterol, pack-year smoking history, alcohol use, presence of extraarticular manifestations, education level, BMI, and number of deformed joints. The latter models in Figure 1 may be overfitted because 14 independent variables were entered, and hence any real difference between the mean cIMT and plaque prevalence between black and white patients could be disguised. However, when we entered disease duration, prednisone use, hypertension, total and HDL cholesterol, pack-year smoking history, alcohol use, the presence of extraarticular manifestations, education level, BMI, and number of deformed joints as potential confounders, each separately and together with age, sex, and healthcare center in different models, the results remained consistently unaltered: the cIMT remained similar in blacks compared to whites ($p = 0.6$ to 1.0) and population or ethnic grouping (EG) remained unassociated with plaque (OR 0.79 to 0.96, 95% CI 0.32–0.96, 95% CI 1.96–2.62, $p = 0.5$ to 0.9) in each of the models.

Disparities in relationships of modifiable CV risk factors with carotid atherosclerosis in black compared to white patients




Figure 1. The carotid artery atherosclerosis burden in black and white Africans with rheumatoid arthritis (RA). **A.** Carotid intima-media thickness (cIMT) in black compared to white patients with RA. **B.** The association of population or ethnic grouping with carotid artery plaque. Results are expressed as mean (SD) and the corresponding *p* value in univariate analysis (Student *t* test) as well as *p* values in confounder-adjusted linear regression models in panel A, and as OR (95% CI) and the corresponding *p* values in univariate and confounder-adjusted logistic regression models in panel B. *Adjusted for age, sex, and healthcare center. †Further adjusted for disease duration and prednisone use as well as cardiovascular risk/predisposing factors that differed between black and white patients (Table 2) and included hypertension, total and HDL cholesterol, pack-year smoking history, alcohol use, presence of extraarticular manifestation, education, body mass index, and number of deformed joints.

with RA. In age, sex, and healthcare-adjusted analysis in all patients, these factors were associated with the cIMT: hypertension [partial correlation coefficient in multivariable linear regression model (ρ) = 0.13, *p* = 0.04], log HDL cholesterol concentrations (ρ = -0.16, *p* = 0.01), LDL cholesterol concentrations (ρ = 0.15, *p* = 0.02), non-HDL cholesterol concentrations (ρ = 0.13, *p* = 0.04), BMI (ρ = 0.13, *p* = 0.04), and DAS28 (ρ = 0.13, *p* = 0.04). No CV risk factors were associated with plaque in all patients.

Interactions between EG and recorded individual CV risk factors (Table 2) that were associated with cIMT in all patients independent of confounders and individual terms are shown in Table 3; they comprised EG \times systolic blood pressure, EG \times total cholesterol/HDL cholesterol ratio, EG \times CRP concentra-

tion, and EG \times AIMS tension score. In stratified analysis, the systolic blood pressure, total cholesterol/HDL cholesterol, and CRP concentration were associated with the cIMT in white but not in black patients; conversely, the AIMS tension score was related to the cIMT in black but not in white patients. In an additional model, systolic blood pressure (ρ = 0.21, *p* = 0.03), total cholesterol/HDL cholesterol (ρ = 0.21, *p* = 0.03), and CRP concentration (ρ = 0.21, *p* = 0.03) were associated with cIMT in whites, independent of one another and of confounders; further, the association of the AIMS tension score with cIMT among black patients with RA was materially unaltered (ρ = 0.18, *p* = 0.07) after adjustment for socioeconomic factors as potential confounders and comprising marital status, education, alcohol use, and pack-year smoking history.

Table 3. Associations of modifiable CV risk factors with common carotid intima-media thickness (cIMT) in black and white patients with RA separately. Significant associations are shown in bold type.

CV Risk Factor	Black and White Patients Combined Interaction p	Stratified Analysis			
		Blacks Partial R* p	Whites Partial R* p		
Systolic blood pressure	0.005	-0.06	0.4	0.24	0.01
Total chol/HDL chol	0.01	0.05	0.6	0.26	0.004
C-reactive protein [†]	0.01	0.11	0.2	0.24	0.01
AIMS tension [†]	0.005	0.19	0.04	0.06	0.5

CV: cardiovascular; chol: cholesterol; AIMS: Arthritis Impact Measurement Scales; HDL: high-density lipoprotein. * Partial correlation coefficients in multivariable regression models in which age, sex, and healthcare center were entered as potentially confounding variables. † Log transformed.

Interactions between EG and CV risk factors that were independently associated with carotid artery plaque are shown in Table 4; they comprised EG × systolic blood pressure, EG × extraarticular manifestations, EG × AIMS tension score, and EG × NSAID use. In stratified analysis, systolic blood pressure and presence of extraarticular manifestations were associated with plaque in white but not black patients; conversely, the AIMS tension score and NSAID use were related to plaque in black but not white patients. In additional models, systolic blood pressure (OR per 10-mm Hg increase = 1.37, 95% CI 1.03–1.82, $p = 0.03$) and the presence of extraarticular manifestations (OR 5.83, 95% CI 1.34–25.39, $p = 0.02$) in white patients and the AIMS tension score (0 to 10 scale; OR 1.42, 95% CI 1.05–1.92, $p = 0.02$) and NSAID use (OR 6.75, 95% CI 1.57–39.33, $p = 0.03$) in black patients were associated with plaque, independent of one another and confounders. Further, among black patients, the association of the AIMS tension score with plaque with RA was materially unaltered (OR 1.31, 95% CI 1.00–1.74, $p = 0.05$) after adjustment for socioeconomic factors as potential confounders and comprising marital status, education, alcohol use, and pack-year smoking history, and the association of NSAID use with plaque was independent of prednisone and DMARD use.

The analysis revealed that major conventional CV risk factors were related to the cIMT in white but not in black

patients. This was confirmed upon assessment of whether the association of overall major conventional CV risk as estimated by the Framingham score with cIMT differed by ethnic group. Thus, the interaction term EG × Framingham score was associated with the cIMT independent of healthcare center and individual terms ($p = 0.002$; age and sex were not adjusted for in the respective model since these characteristics are used in calculating the Framingham score). In stratified analysis, the Framingham score was significantly associated with cIMT in white ($pr = 0.47$, $p < 0.0001$) but not in black ($pr = 0.18$, $p = 0.06$) patients.

DISCUSSION

We found the carotid artery atherosclerosis burden sustained by black Africans with established RA was similar to that in whites. An increased cIMT in the presence of hypertension may reflect arterial medial-layer hypertrophy rather than atheroma³⁷. The cIMT was, however, similar in African black and white patients independent of a diagnosis of hypertension. Additionally, we found a marked variation in the independent associations between modifiable CV risk factors and atherosclerosis among black and white patients with RA. Our main findings each originated in several multivariable regression models adjusted for confounders. To our knowledge, this is the first study that simultaneously assessed and directly compared the atherosclerosis burden and its relationships with CV

Table 4. Associations of modifiable CV risk factors with carotid artery plaque in black and white patients separately. Significant associations are shown in bold type.

CV Risk Factor	Black and White Patients Combined Interaction p	Stratified Analysis			
		Blacks OR (95% CI)* p	Whites OR (95% CI)* p		
Systolic blood pressure/10, range 9–21.3 in black and 9.8–19 in white patients	0.01	0.88 (0.74–1.05)	0.2	1.38 (1.04–1.84)	0.02
Extraarticular manifestations, yes vs no	0.05	0.72 (0.05–9.89)	0.8	5.88 (1.42–24.45)	0.01
AIMS tension [†] , range 0–10	0.04	1.41 (1.04–1.90)	0.02	0.99 (0.92–1.06)	0.9
NSAID use, yes vs no	0.02	5.97 (1.60–23.85)	0.03	1.00 (0.97–1.02)	0.4

CV: cardiovascular; AIMS: Arthritis Impact Measurement Scales; NSAID: nonsteroidal antiinflammatory drug. * Adjusted for age, sex, and healthcare center. † Log transformed and normalized to a 0 to 10 range.

risk factors between patients with RA that belong to a developing and a developed population.

The acquisition of western lifestyles resulting in emerging CVD risk factors and events was recently documented in non-RA black Africans^{18,22}. Nevertheless, CVD is still confirmed in only 6% of black South Africans that present to hospital with heart disease³⁸. Our finding of a similar atherosclerosis burden in black and white patients with RA confirms that in the presence of RA, protection against CVD, mediated by the earlier epidemiological transition stage, may be absent in black Africans¹⁸.

Because hypertension was more frequent and the mean atherogenic index and CRP concentrations were similar in black compared to white patients in our study, it is particularly striking that the respective risk factors as well as the Framingham score were associated with atherosclerosis in whites only. This finding has 2 potential implications. First, major conventional CV risk factors and systemic inflammation may not be reliable in estimating CVD risk in black Africans that have developed established RA. This is in sharp contrast with reported findings in studies that were performed in developed populations and are congruous with our current results obtained in whites^{3,4,5,6,7,8,9,10}. Because ultrasonographically identified atherosclerosis including both carotid cIMT and plaque was shown to predict CVD events not only in non-RA subjects but also in patients with RA and independent of population origin^{25,26,39}, our results suggest that the use of direct vascular imaging may be more frequently indicated in optimal CV risk assessment in patients with RA from developing populations. Second, atherogenesis in black Africans with RA needs further investigation. The absence of associations of hypertension and dyslipidemia with atherosclerosis among black Africans with RA in our analysis does not exclude a role of major conventional risk factors in atherogenesis. Rather, because black Africans are currently undergoing a rapid socioeconomic transition^{18,20,22}, upon reaching a mean age of 56 years as applied to those enrolled in our study, they are likely to sustain a shorter lifetime exposure to unhealthy lifestyles that could have contributed to our findings. Equally relevant, we recently reported that, compared to British white subjects, non-RA black Africans experience much greater aortic reflective waves and hence possibly greater aortic blood pressure values for a given brachial blood pressure⁴⁰, and black Africans have reduced nocturnal blood pressure dipping that may produce target organ effects independent of conventional blood pressure⁴¹. Finally, we found that CRP concentrations were associated with atherosclerosis only in white Africans with RA. Interestingly, we recently documented prevalent high CRP concentrations in non-RA black Africans that were also not independently related to CVD risk as assessed by increases in aortic pulse pressure, the component waves, or the determinants of central pulse pressure⁴². Taken together, the potential contributions of major conventional risk factors and systemic inflammation to

atherogenesis in black Africans with RA require assessment in future longitudinal studies and possibly central rather than brachial blood pressure evaluation⁴⁰, the use of ambulatory 24-hour day and night blood pressure recording⁴¹, and direct measurement of inflamed joint-derived circulating cytokine concentrations^{43,44,45}.

We found that the presence of extraarticular manifestations that reflect RA severity⁴⁶ was independently associated with atherosclerosis in whites only. This disease characteristic was previously shown to be associated with atherosclerosis⁴⁷ and to predict CV mortality in RA⁴⁶. However, in keeping with an earlier report⁴⁸, extraarticular disease was distinctly uncommon in black Africans with RA (2.5% vs 12.3% in whites; adjusted OR 0.19), and therefore a larger study may be required to adequately assess its potential influence on atherogenesis in patients with RA from this population.

Vascular reactivity to psychological stress is enhanced in black compared to white subjects and is associated with an increased susceptibility to atherosclerosis and incident CV events^{49,50,51}. Stress reduction was shown to reduce carotid atherosclerosis and CV mortality in black Americans⁵². In our investigation, the AIMS tension score was independently associated with both the cIMT and plaque in black Africans with RA and not in whites; and in multivariable analysis, marital status, low education level, and smoking and alcohol use did not materially alter this relationship. Our results support the presence of an enhanced interconnectedness between mental and physical health²³ that should be considered in optimal CVD prevention in black Africans with RA.

Selective COX-2 inhibition can enhance thrombosis risk and the development of hypertension⁵³. However, the use of both traditional NSAID and selective COX-2 inhibitors increases CV event rates⁵⁴. Variable effects of these agents in terms of atheroma development were reported in animal studies⁵³. In our cohort, traditional NSAID use independently increased the OR for plaque 6-fold in black Africans with RA.

In addition to an earlier epidemiological health transition stage in black compared to white Africans, genetic differences between patients with RA from the 2 ethnic groups may alternatively or additionally support our findings. Indeed, in studies that included black and white populations, a different ethnic distribution of genetic polymorphisms that are associated with CVD, hypertension, and circulating lipid and CRP concentrations was found^{55,56,57,58,59,60}. Further, specific patterns of associations between genetic variations in beta-adrenoreceptors and not only cold and but also psychological stress have been reported in young black individuals⁶¹. Finally, the potential importance of documented variations in CVD-related COX polymorphisms among white and black Americans⁶² deserves further study.

Compared to their white counterparts, black Africans with RA experience a similar burden of carotid atherosclerosis. These findings call for intensive CV risk management irrespective of epidemiological transition stage or population ori-

gin in patients with RA. However, relationships between cross-sectionally recorded modifiable risk factors and atherosclerosis vary considerably among Africans with RA. Longitudinal studies and possibly other than conventional CV risk factor evaluations are needed to further elucidate atherogenesis and optimal CV risk assessment in black Africans with RA.

REFERENCES

1. Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. *Arch Cardiovasc Dis* 2010;103:253-61.
2. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. *Arthritis Rheum* 2008;59:1690-7.
3. Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. *J Rheumatol* 2005;32:435-42.
4. Gonzalez-Gay MA, Gonzalez-Juanatey C, Pineiro A, Garcia-Porrúa C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. *J Rheumatol* 2005;32:1219-23.
5. del Rincon I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. *Arthritis Rheum* 2005;52:3413-23.
6. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: Relationship to disease duration and cardiovascular risk factors. *Arthritis Rheum* 2005;52:3045-53.
7. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. *Ann Intern Med* 2006;144:249-56.
8. Kremers HM, Crowson CS, Themeau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: A population-based cohort study. *Arthritis Rheum* 2008;58:2268-74.
9. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis. *Arthritis Rheum* 2008;58:2612-21.
10. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severity. *Ann Rheum Dis* 2010;69:1920-5.
11. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. *N Engl J Med* 1994;330:1041-6.
12. Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Palomino-Morales R, Vazquez-Rodriguez TR, Miranda-Fillooy JA, Fernandez-Gutierrez B, et al. TNFA-308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. *Atherosclerosis* 2011;216:125-30.
13. Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Garcia-Bermudez M, Vazquez-Rodriguez TR, Miranda-Fillooy JA, Fernandez-Gutierrez B, et al. CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: A cohort study. *Arthritis Res Ther* 2011;13:R133.
14. Teruel M, Martin JE, Gonzalez-Juanatey C, Lopez-Mejias R, Miranda-Fillooy JA, Blanco R, et al. Association of acid phosphatase locus 1* C allele with the risk of cardiovascular events in rheumatoid arthritis patients. *Arthritis Res Ther* 2011;13:R116.
15. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrúa C, Miranda-Fillooy JA, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. *Arthritis Rheum* 2007;57:125-32.
16. Toms TE, Panoulas VF, Smith JP, Douglas KM, Metsios GS, Stavropoulos-Kalinoglou A, et al. Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. *Ann Rheum Dis* 2011;70:1025-32.
17. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. *Lancet* 2004;364:937-52.
18. Solomon A, Christian BF, Norton GR, Woodiwiss AJ, Dessein PH. Risk factor profiles for atherosclerotic cardiovascular disease in black and other Africans with established rheumatoid arthritis. *J Rheumatol* 2010;37:953-60.
19. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases, Part 1: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation* 2001;104:2746-53.
20. Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, Damasceno A, et al. Risk factors associated with myocardial infarction in Africa. The INTERHEART Africa Study. *Circulation* 2005;112:3554-61.
21. Bhorat H. South Africa has the widest gap between rich and poor. Sept 28 2009. [Internet. Accessed May 24, 2012.] Available from: www.busrep.co.za
22. Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D. The burden of non-communicable diseases in South Africa. *Lancet* 2009;374:934-47.
23. Solomon A, Christian BF, Woodiwiss AJ, Norton GR, Dessein PH. Burden of depressive symptoms in South African public healthcare patients with established rheumatoid arthritis: A case-control study. *Clin Exp Rheumatol* 2011;29:506-12.
24. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidemias: The Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 2011;32:1769-818.
25. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. *Semin Arthritis Rheum* 2009;38:366-71.
26. Evans MR, Escalante A, Battafarano DF, Freeman GL, O'Leary DH, del Rincon I. Carotid atherosclerosis predicts incident acute coronary syndrome in rheumatoid arthritis. *Arthritis Rheum* 2011;63:1211-20.
27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
28. National HIV prevalence in South Africa. 13 November 2005. [Internet. Accessed May 24, 2012.] Available from: <http://www.hsrc.ac.za/Factsheet-40.phtml>
29. Toms TE, Panoulas VF, Douglas KM, Nightingale P, Smith JP, Griffiths H, et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis? *Angiology* 2011;62:167-75.
30. Dessein PH, Christian BF, Solomon A. Which are the determinants of dyslipidemia in rheumatoid arthritis and does socioeconomic status matter in this context? *J Rheumatol* 2009;36:1357-61.

31. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The Arthritis Impact Measurement Scales. *Arthritis Rheum* 1980;23:146-52.
32. Turesson C, Jacobsson L, Bergstrom U. Extra-articular rheumatoid arthritis: Prevalence and mortality. *Rheumatology* 1999;38:668-74.
33. Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: A population-based study. *J Rheumatol* 2011;38:983-9.
34. Gepner AD, Korcarz CE, Aeschlimann SE, LeCaire TJ, Palta M, Tzou WS, et al. Validation of a carotid intima-media thickness border detection program for use in an office setting. *J Am Soc Echocardiogr* 2006;19:223-8.
35. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarencu P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. *Cerebrovasc Dis* 2007;23:75-80.
36. Chambless LE, Heiss, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid artery wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. *Am J Epidemiol* 1997;146:483-94.
37. del Rincon I. Atherosclerosis in rheumatoid arthritis: What to look for in studies using carotid ultrasound. *J Rheumatol* 2010;37:890-3.
38. Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, et al. Spectrum of heart disease and risk factors in an urban population in South Africa (The Heart of Soweto Study): A cohort study. *Lancet* 2008;317:915-22.
39. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2010;56:e50-103.
40. Chirinos JA, Kips JG, Roman MJ, Medina-Lezama J, Li Y, Woodiwiss AJ, et al. Ethnic differences in arterial wave reflections and normative equations for augmentation index. *Hypertension* 2011;57:1108-16.
41. Maseko MJ, Woodiwiss AJ, Majane OH, Molebatsi N, Norton GR. Marked underestimation of blood pressure control with conventional vs. ambulatory measurements in an urban, developing community of African ancestry. *Am J Hypertens* 2011;24:789-95.
42. Redelinghuys M, Norton GR, Janse van Rensburg NM, Maseko MJ, Majane HI, Dessein PH, et al. Lack of independent association between C-reactive protein and central aortic hemodynamics in black Africans with high risk of cardiovascular disease. *Am J Hypertens* 2011;24:1094-101.
43. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. *Arthritis Res Ther* 2005;7:R634-43.
44. Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, Sokka T, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. *Arthritis Rheum* 2009;61:1580-5.
45. Marder W, Khalatbari S, Myles JD, Hench R, Yalavarthi S, Lustig S, et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. *Ann Rheum Dis* 2011;70:1550-5.
46. Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. *Ann Rheum Dis* 2007;66:70-5.
47. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrúa C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. *Medicine* 2003;82:407-13.
48. Chikanza IC, Stein M, Lutalo S, Gibson T. The clinical, serologic and radiologic features of rheumatoid arthritis in ethnic black Zimbabwean and British Caucasian patients. *J Rheumatol* 1994;32:2011-5.
49. Roemmich JN, Fedá DM, Seelbinder AM, Lambiasi MJ, Kala GK, Dorn J. Stress-induced cardiovascular reactivity and atherogenesis in adolescents. *Atherosclerosis* 2011;215:465-70.
50. Chida Y, Steptoe A. Greater cardiovascular responses to laboratory mental stress are associated with poor subsequent cardiovascular risk status: A meta-analysis of prospective evidence. *Hypertension* 2010;55:1026-32.
51. Taherzadeh Z, Brewster LM, van Montfrans GA, VanBavel E. Function and structure of resistance vessels in black and white people. *J Clin Hypertens* 2010;12:431-8.
52. Castillo-Richmond A, Schneider RH, Alexander CN, Cook R, Myers H, Nidich S, et al. Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. *Stroke* 2000;31:568-73.
53. Funk CD, FitzGerald GA. Cox-2 inhibitors and cardiovascular risk. *J Cardiovasc Pharmacol* 2007;50:470-9.
54. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. *BMJ* 2011;342:c7086.
55. Loktionov A, Vorster H, O'Neill IK, Nell T, Bingham SA, Runswick SA, et al. Apolipoprotein E and methylenetetrahydrofolate reductase genetic polymorphisms in relation to other risk factors for cardiovascular disease in UK Caucasians and Black South Africans. *Atherosclerosis* 1999;145:125-35.
56. Siffert W, Forster P, Jockel K-H, Mvere DA, Brinkmann B, Naber C, et al. Worldwide ethnic distribution of the G protein $\beta 3$ submit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. *J Am Soc Nephrol* 1999;10:1921-30.
57. Wood AJ. Variability in beta-adrenergic receptor response in the vasculature: Role of receptor polymorphism. *J Allergy Clin Immunol* 2002;110 Suppl:S318-21.
58. Chang M-H, Yesupriya A, Ned RM, Mueller PW, Dowling NF. Genetic variants associated with fasting blood lipids in the U.S. population: Third National Health and Nutrition Examination Survey. *BMC Med Genetics* 2010;11:62.
59. Pablos-Mendez A, Mayeux R, Ngai C, Shea S, Berglund L. Association of Apo E polymorphism with plasma lipid levels in a multiethnic elderly population. *Arterioscler Thromb Vas Biol* 1997;17:1534-41.
60. Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C, et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. *Diabetes* 2008;57:3112-21.
61. Kelsey RM, Alpert BS, Dahmer MK, Krushkal J, Quasney MW. Beta-adrenergic receptor gene polymorphisms and cardiovascular reactivity to stress in Black adolescents and young adults. *Psychophysiology* 2010;47:863-73.
62. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) study. *Clin Pharmacol Ther* 2008;83:52-60.